Drug intelligence / Profile preview

MSC-Delta-24-RGD

Development stage: Unknown
Lead developer: University of Texas MD Anderson Cancer Center
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Stem Cell Therapies → Cell Therapies
Administration: Intra-arterial, Intratumoral

Overview

MSC-Delta-24-RGD is an investigational cell-based oncolytic viral therapy designed to treat high-grade gliomas. It consists of human bone marrow-derived mesenchymal stem cells (hMSCs) loaded with Delta-24-RGD (also known as DNX-2401), a replication-competent oncolytic adenovirus. The virus is engineered with a 24-base pair deletion in the E1A gene, which restricts its replication to tumor cells with a deficient retinoblastoma (RB) pathway, and an RGD-4C motif in the fiber protein to enhance entry into tumor cells via integrins. The MSC carrier acts as a delivery vehicle, exploiting the natural tumor-homing properties of stem cells to enhance the intravascular delivery of the virus to the tumor microenvironment while protecting it from neutralizing antibodies. This therapy is primarily being evaluated for the treatment of recurrent glioblastoma and other high-grade brain tumors, including pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG).

Other names: mesenchymal stem cells carrying Delta-24-RGD

Targets

CXADR (Coxsackievirus and adenovirus receptor)RB1 (Retinoblastoma-associated Protein)αVβ3 (Integrin αVβ3)αVβ5 (Integrin αVβ5)

Beyond the preview

Go deeper on MSC-Delta-24-RGD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC-Delta-24-RGD.

Explore the full profile